Adult-onset Still's disease: current challenges and future prospects

Adult-onset Still's disease: current challenges and future prospects

Mariam Siddiqui,1 Michael S Putman,2 Anisha B Dua,11Department of Rheumatology, 2Department of Internal Medicine, The University of Chicago Medical Center, Chicago, IL, USA Abstract: Adult-onset Still's disease (AOSD) – a multi-systemic inflammatory condition characterized by high...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Siddiqui M, Putman MS, Dua AB
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
Adult onset Stills Disease
Biomarkers
Therapeutics
Diseases of the musculoskeletal system
RC925-935
Acceso en línea:https://doaj.org/article/3cbf2ff39b6c42a694b0fb84f7b31c04
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3cbf2ff39b6c42a694b0fb84f7b31c04
record_format dspace
spelling oai:doaj.org-article:3cbf2ff39b6c42a694b0fb84f7b31c042021-12-02T00:44:50ZAdult-onset Still's disease: current challenges and future prospects1179-156Xhttps://doaj.org/article/3cbf2ff39b6c42a694b0fb84f7b31c042016-03-01T00:00:00Zhttps://www.dovepress.com/adult-onset-still39s-disease-current-challenges-and-future-prospects-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XMariam Siddiqui,1 Michael S Putman,2 Anisha B Dua,11Department of Rheumatology, 2Department of Internal Medicine, The University of Chicago Medical Center, Chicago, IL, USA Abstract: Adult-onset Still's disease (AOSD) – a multi-systemic inflammatory condition characterized by high fevers, polyarthritis, an evanescent rash, and pharyngitis – has been a challenging condition to diagnose expediently and treat effectively. Questions remain regarding the underlying pathophysiology and etiology of AOSD. Pathognomonic diagnostic tests and reliable biomarkers remain undiscovered. Over the past decade, important progress has been made. Diagnostic criteria employing glycosylated ferritin have improved specificity. More important, novel biologic therapies have offered important clues to AOSD's underlying pathophysiology. Cytokine-specific biologic therapies have been instrumental in providing more effective treatment for disease refractory to conventional treatment. While IL-1 therapy has demonstrated efficacy in refractory disease, novel therapies targeting IL-6 and IL-18 show great promise and are currently under investigation. Keywords: adult-onset Still's disease, biomarkers, therapeuticsSiddiqui MPutman MSDua ABDove Medical PressarticleAdult onset Stills DiseaseBiomarkersTherapeuticsDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2016, Iss Issue 1, Pp 17-22 (2016)
institution DOAJ
collection DOAJ
language EN
topic Adult onset Stills Disease
Biomarkers
Therapeutics
Diseases of the musculoskeletal system
RC925-935
spellingShingle Adult onset Stills Disease
Biomarkers
Therapeutics
Diseases of the musculoskeletal system
RC925-935
Siddiqui M
Putman MS
Dua AB
Adult-onset Still's disease: current challenges and future prospects
description Mariam Siddiqui,1 Michael S Putman,2 Anisha B Dua,11Department of Rheumatology, 2Department of Internal Medicine, The University of Chicago Medical Center, Chicago, IL, USA Abstract: Adult-onset Still's disease (AOSD) – a multi-systemic inflammatory condition characterized by high fevers, polyarthritis, an evanescent rash, and pharyngitis – has been a challenging condition to diagnose expediently and treat effectively. Questions remain regarding the underlying pathophysiology and etiology of AOSD. Pathognomonic diagnostic tests and reliable biomarkers remain undiscovered. Over the past decade, important progress has been made. Diagnostic criteria employing glycosylated ferritin have improved specificity. More important, novel biologic therapies have offered important clues to AOSD's underlying pathophysiology. Cytokine-specific biologic therapies have been instrumental in providing more effective treatment for disease refractory to conventional treatment. While IL-1 therapy has demonstrated efficacy in refractory disease, novel therapies targeting IL-6 and IL-18 show great promise and are currently under investigation. Keywords: adult-onset Still's disease, biomarkers, therapeutics
format article
author Siddiqui M
Putman MS
Dua AB
author_facet Siddiqui M
Putman MS
Dua AB
author_sort Siddiqui M
title Adult-onset Still's disease: current challenges and future prospects
title_short Adult-onset Still's disease: current challenges and future prospects
title_full Adult-onset Still's disease: current challenges and future prospects
title_fullStr Adult-onset Still's disease: current challenges and future prospects
title_full_unstemmed Adult-onset Still's disease: current challenges and future prospects
title_sort adult-onset still's disease: current challenges and future prospects
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/3cbf2ff39b6c42a694b0fb84f7b31c04
work_keys_str_mv AT siddiquim adultonsetstill39sdiseasecurrentchallengesandfutureprospects
AT putmanms adultonsetstill39sdiseasecurrentchallengesandfutureprospects
AT duaab adultonsetstill39sdiseasecurrentchallengesandfutureprospects
_version_ 1718403487655526400

Ejemplares similares